{"id":5320,"date":"2023-07-06T07:30:31","date_gmt":"2023-07-06T07:30:31","guid":{"rendered":"https:\/\/www.rheuma.be\/?post_type=working-groups&#038;p=5320"},"modified":"2024-03-23T21:52:42","modified_gmt":"2024-03-23T21:52:42","slug":"immuno-oncology","status":"publish","type":"working-groups","link":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/","title":{"rendered":"Immuno-oncology"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"5320\" class=\"elementor elementor-5320\" data-elementor-post-type=\"working-groups\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1558852 e-flex e-con-boxed e-con e-parent\" data-id=\"1558852\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fea1389 elementor-widget elementor-widget-text-editor\" data-id=\"fea1389\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span lang=\"EN-US\">In 2017, a collaboration between The Belgian Society of Medical Oncology and the KVBR\/SRBR was launched. The first achievement was the local guidelines for diagnosis and treatment of immune related adverse events in patients treated with immunotherapies for their cancer. They are accessible on the<a href=\"https:\/\/www.bsmo.be\/immunomanager\/\" target=\"_blank\" rel=\"noopener\"> ImmunoManager website<\/a>.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e86d7ff elementor-widget elementor-widget-heading\" data-id=\"e86d7ff\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Group Leaders<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-892fbc2 elementor-widget elementor-widget-text-editor\" data-id=\"892fbc2\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Dr. Sandrine Aspeslagh (Oncologist)<\/li><li>Dr. Laurent Meric de Bellefon (rhumatologue)<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d90a30e elementor-widget elementor-widget-heading\" data-id=\"d90a30e\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Group objectives<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-faff09a elementor-widget elementor-widget-text-editor\" data-id=\"faff09a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"x_MsoNormal\"><span lang=\"EN-US\">As \u201corgan specialists\u201d, members of the working group regularly attend\u00a0<u>National Multidisciplinary Immunotoxicity<\/u>\u00a0board meetings (every 2 weeks). Those meetings are led by our oncologist colleagues and are online.\u00a0<br \/><\/span><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">Our tasks are to give an opinion on the diagnosis of the new musculoskeletal adverse event, or the pre-existing auto-immune disease in the context of the immunotherapy. <br \/>We help the oncologists regarding the immunosuppression.<\/span><\/p><p class=\"x_MsoNormal\"><span lang=\"EN-US\">The BSMO-KVBR\/SRBR collaboration made it possible to carry out scientific work such as:<br \/><\/span><span lang=\"EN-US\" style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">&#8211; Lauwyck J, Schreuer M, Meric de Bellefon L, Van Erps J, Neyns B, Aspeslagh S. Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports. Melanoma Res. 2022 Jun 1;32(3):200-204. doi: 10.1097\/CMR.0000000000000814. Epub 2022 Mar 29. PMID: 35377860.<\/span><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\"><br \/><\/span><\/p><p class=\"x_MsoNormal\"><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">&#8211; <a href=\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2024\/03\/poster-BCR-immuno-oncology.pdf\" target=\"_blank\" rel=\"noopener\">BCR ABSTRACT 2022:<\/a> Musculoskeletal immune related adverse events in patients treated with checkpoint inhibitors :a multicentric retrospective study\u00a0. Meric de Bellefon L.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">1<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Sokolova T.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">1<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">,Malaise O.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">2<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">,Wittoek R.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">3<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Aerts N.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">4<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Piette Y.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">5<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Neerinckx B.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">6<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Verhaert M.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">7<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Aspeslagh S.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">7<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">, Durez P.<\/span><sup style=\"text-align: var(--text-align); color: var( --e-global-color-text ); letter-spacing: 0.7px;\">1<\/sup><span style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">\u00a0<\/span><\/p><p class=\"x_MsoNormal\"><span lang=\"EN-GB\">Some local initiatives are also accessible to all rheumatologists:<br \/><\/span><span lang=\"EN-GB\" style=\"text-align: var(--text-align); color: var( --e-global-color-text ); font-size: 1.6rem; letter-spacing: 0.7px;\">&#8211; PISCO study: Pathophysiology of Induced Synovitis with Checkpoint inhibitors in Oncology. Patients with induced-arthritis undergo a synovial biopsy (ultrasound guided or with needle miniarthroscopy). Histology, immunohistochemistry and gene expression are studied on the synovial fragments.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-58d4617 elementor-widget elementor-widget-image\" data-id=\"58d4617\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"447\" src=\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png\" class=\"attachment-large size-large wp-image-10392\" alt=\"\" srcset=\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png 1024w, https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-300x167.png 300w, https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-768x429.png 768w, https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1536x857.png 1536w, https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432.png 1897w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"template":"","class_list":["post-5320","working-groups","type-working-groups","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immuno-oncology - Rheuma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuno-oncology - Rheuma\" \/>\n<meta property=\"og:description\" content=\"In 2017, a collaboration between The Belgian Society of Medical Oncology and the KVBR\/SRBR was launched. The first achievement was the local guidelines for diagnosis and treatment of immune related adverse events in patients treated with immunotherapies for their cancer. They are accessible on the ImmunoManager website. Group Leaders Dr. Sandrine Aspeslagh (Oncologist) Dr. Laurent [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Rheuma\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-23T21:52:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/\",\"url\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/\",\"name\":\"Immuno-oncology - Rheuma\",\"isPartOf\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png\",\"datePublished\":\"2023-07-06T07:30:31+00:00\",\"dateModified\":\"2024-03-23T21:52:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage\",\"url\":\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png\",\"contentUrl\":\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Working groups\",\"item\":\"https:\/\/www.rheuma.be\/nl\/working-groups\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuno-oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/#website\",\"url\":\"https:\/\/www.rheuma.be\/nl\/\",\"name\":\"Rheuma\",\"description\":\"KBVR\",\"publisher\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rheuma.be\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/#organization\",\"name\":\"De Koninklijke Belgische Vereniging voor Reumatologie\",\"alternateName\":\"KBVR\",\"url\":\"https:\/\/www.rheuma.be\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/www.rheuma.be\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/05\/rheuma.be-donate.webp\",\"contentUrl\":\"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/05\/rheuma.be-donate.webp\",\"width\":1498,\"height\":464,\"caption\":\"De Koninklijke Belgische Vereniging voor Reumatologie\"},\"image\":{\"@id\":\"https:\/\/www.rheuma.be\/nl\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuno-oncology - Rheuma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/","og_locale":"nl_NL","og_type":"article","og_title":"Immuno-oncology - Rheuma","og_description":"In 2017, a collaboration between The Belgian Society of Medical Oncology and the KVBR\/SRBR was launched. The first achievement was the local guidelines for diagnosis and treatment of immune related adverse events in patients treated with immunotherapies for their cancer. They are accessible on the ImmunoManager website. Group Leaders Dr. Sandrine Aspeslagh (Oncologist) Dr. Laurent [&hellip;]","og_url":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/","og_site_name":"Rheuma","article_modified_time":"2024-03-23T21:52:42+00:00","og_image":[{"url":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"2 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/","url":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/","name":"Immuno-oncology - Rheuma","isPartOf":{"@id":"https:\/\/www.rheuma.be\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png","datePublished":"2023-07-06T07:30:31+00:00","dateModified":"2024-03-23T21:52:42+00:00","breadcrumb":{"@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#primaryimage","url":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png","contentUrl":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/07\/Capture-decran-2024-03-23-224432-1024x572.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rheuma.be\/nl\/working-groups\/immuno-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Working groups","item":"https:\/\/www.rheuma.be\/nl\/working-groups\/"},{"@type":"ListItem","position":2,"name":"Immuno-oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.rheuma.be\/nl\/#website","url":"https:\/\/www.rheuma.be\/nl\/","name":"Rheuma","description":"KBVR","publisher":{"@id":"https:\/\/www.rheuma.be\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rheuma.be\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.rheuma.be\/nl\/#organization","name":"De Koninklijke Belgische Vereniging voor Reumatologie","alternateName":"KBVR","url":"https:\/\/www.rheuma.be\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.rheuma.be\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/05\/rheuma.be-donate.webp","contentUrl":"https:\/\/www.rheuma.be\/wp-content\/uploads\/2023\/05\/rheuma.be-donate.webp","width":1498,"height":464,"caption":"De Koninklijke Belgische Vereniging voor Reumatologie"},"image":{"@id":"https:\/\/www.rheuma.be\/nl\/#\/schema\/logo\/image\/"}}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Team","author_link":"https:\/\/www.rheuma.be\/nl\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"In 2017, a collaboration between The Belgian Society of Medical Oncology and the KVBR\/SRBR was launched. The first achievement was the local guidelines for diagnosis and treatment of immune related adverse events in patients treated with immunotherapies for their cancer. They are accessible on the ImmunoManager website. Group Leaders Dr. Sandrine Aspeslagh (Oncologist) Dr. Laurent&hellip;","_links":{"self":[{"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/working-groups\/5320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/working-groups"}],"about":[{"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/types\/working-groups"}],"version-history":[{"count":5,"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/working-groups\/5320\/revisions"}],"predecessor-version":[{"id":10397,"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/working-groups\/5320\/revisions\/10397"}],"wp:attachment":[{"href":"https:\/\/www.rheuma.be\/nl\/wp-json\/wp\/v2\/media?parent=5320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}